CARM — Carisma Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.01m
- -$2.77m
- $19.63m
Brief: Sesen Bio Inc- On May 13, Co Requested Type A Meeting With U.S. FDA
Sesen Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sesen Bio Reports First Quarter 2022 Financial Results
Sesen Bio Inc expected to post a loss of 10 cents a share - Earnings Preview
Sesen Bio jumps after starting strategic review of business
Brief: Sesen Bio Says Strategic Alternatives May Include Sale, A Merger
NASDAQ RESUMED AT 08:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Sesen Bio slumps as company plans to meet FDA over bladder cancer drug
Brief: Sesen Bio Says Participated In Type C Meeting With U.S. FDA
Brief: Sesen Bio Reports Fourth Quarter 2021 Results And Anticipated Path Forward For Lead Candidate, Vicineum
Cell, gene therapy companies pressured by supply and manufacturing issues -BTIG
Brief: Sesen Bio Says FDA Granted Co's Request For A Type C Meeting
Brief: Sesen Bio - Will Receive A $20 Million Milestone Payment Pursuant To Co’S Exclusive License Agreement With F. Hoffmann-La Roche Ltd & Hoffman-La Roche Inc
Sesen Bio slides on plans to conduct another cancer drug trial
Brief: Sesen Bio Announces Anticipated Regulatory Path Forward For Vicineum™
Brief: Sesen Bio - On Nov 17, FDA Granted Co's Request For A Type A Meeting To Discuss Recommendations Regarding CRL
Sesen Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Sesen Bio Reports Q3 Earnings Per Share Of $0.36